

Protein’s next era: Discipline, scale, and fewer fairy tales
The protein sector has spent the past decade defined by ambition, abundant capital, and a wave of founders racing to meet growing demand for healthier and more sustainable ingredients. Some delivered genuine breakthroughs. Many did not. Too many companies were funded on enthusiasm rather than evidence, propelled by underinformed investors chasing quick wins instead of meaningful, consumer-driven innovation. The result was noise, momentum, and a widespread belief that capital alone could will a new food system into existence, regardless of fundamentals.That phase is over…
Over the past 12 to 18 months, the market has shifted decisively. Generalist investors have stepped back, valuations have reset, and companies that once raised capital with ease are now struggling to secure even modest rounds. Only those with real innovation, ingredients that perform in the real world, and a credible path to scale are escaping the gravitational pull of a tightening capital environment. Everyone else is learning a hard lesson: hope is not a commercial strategy. Innovation without a route to scale is just a press release.
This correction should not be mistaken for a failure of the category. It is the natural progression of an industry coming of age, and one that was overdue. Early experimentation inevitably gives way to discipline. Novelty gives way to viability. The strongest technologies, teams, and platforms rise, while weaker propositions fall away. The next five years will be defined by companies that can scale, integrate, and deliver tangible value inside global supply chains.
Hope is not a commercial strategy. Innovation without a route to scale is just a press release
Companies that succeed from this point forward will follow a very different rulebook. They will focus on natural ingredients and concise ingredient lists that customers can understand and trust. They will build affordability and the right cost structure into the product from the beginning, rather than attempting a late-stage correction once the economics no longer work. They will also shift the conversation away from technology for its own sake and toward performance and experience. Customers
care about enjoyment, not engineering, and taste, not technical complexity.
For technical teams, this means designing for scale early and working alongside people who have successfully taken products to market multiple times before. It also means being honest about what is technically feasible within real-world constraints. These principles reflect a broader shift underway across the investment landscape. The focus is no longer on novelty. It is on cost, supply chain resilience, climate impact, food security, and economic competitiveness. As weaker players exit the market, the strongest companies will have the opportunity to redefine entire categories.
Consolidation is no longer a future possibility; it is already happening. Strategic M&A is becoming essential as corporates and governments look for assets that can genuinely move the needle. The priority is no longer to fund every idea, but to identify ingredient platforms and technologies capable of reshaping product architectures at industrial scale.
This is where global perspective becomes critical. We have built teams in New York, Paris, Singapore, and the MENA region, and worked with select corporate partners to find, invest in, and evaluate companies for strategic M&A. Through this global platform, we have real-time visibility into what is emerging, what is working, and where the strongest opportunities lie. It allows us to compare technologies across regions, assess commercial readiness, and identify patterns that are difficult to see from any single market. In a sector moving this quickly, visibility is a competitive advantage.
The next five years will determine which companies become essential to the global food system and which fade into the footnotes of the hype era. The winners will combine real innovation with credible paths to scale, strong commercial traction, and the right partnerships with global leaders and regional stakeholders. The next chapter of protein will be written by strategists and the partnerships they build, not by optimists. The future will be defined by those who make the right decisions now.
Andrew D. Ive is the Founder/Managing General Partner, at Big Idea Ventures. He is an advisory board member for Tufts Nutrition Council, is a Friedman School Entrepreneurship advisor, Harvard Business School graduate, Procter & Gamble brand management trained, and has spent a number of years as an entrepreneur growing companies. This article is republished from the Q4 2025 edition of Protein Production Technology International, the industry's leading resource for alternative proteins. To subscribe to all future editions, please click here
If you have any questions or would like to get in touch with us, please email info@futureofproteinproduction.com
More Opinion

Food biomanufacturing: A national security issue

Creating a new protein sector: Part II

Trade secrets: when, how and why to use them

The criticality of conducting LCAs

Creating a new protein sector: Part I

Protecting IP on a budget

Will the UK become the new Singapore?








